J
Johan Maertens
Researcher at Universitaire Ziekenhuizen Leuven
Publications - 37
Citations - 1893
Johan Maertens is an academic researcher from Universitaire Ziekenhuizen Leuven. The author has contributed to research in topics: Transplantation & Voriconazole. The author has an hindex of 17, co-authored 37 publications receiving 1424 citations. Previous affiliations of Johan Maertens include University of Mainz & University of Manchester.
Papers
More filters
Journal ArticleDOI
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Francisco M. Marty,Per Ljungman,Roy F. Chemaly,Johan Maertens,Sanjeet Dadwal,Rafael F. Duarte,Shariq Haider,Andrew J. Ullmann,Yuta Katayama,Janice M. Brown,Kathleen M. Mullane,Michael Boeckh,Emily A. Blumberg,Hermann Einsele,David R. Snydman,Yoshinobu Kanda,Mark J. DiNubile,Valerie L Teal,Hong Wan,Yoshihiko Murata,Nicholas A. Kartsonis,Randi Y. Leavitt,Cyrus Badshah +22 more
TL;DR: Letermovir prophylaxis resulted in a significantly lower risk of clinically significant CMV infection than placebo, and the frequency and severity of adverse events were similar in the two groups overall.
Journal ArticleDOI
European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia
Johan Maertens,Corrado Girmenia,Roger J. M. Brüggemann,Rafael F. Duarte,Christopher C. Kibbler,Per Ljungman,Zdeněk Ráčil,Patricia Ribaud,Slavin,Slavin,Oliver A. Cornely,Bart Jan Kullberg,Willem J. G. Melchers,Catherine Cordonnier,J.P. Donnelly +14 more
TL;DR: The European Conference on Infections in Leukaemia (ECIL) updated its guidelines on antifungal prophylaxis for adults using the grading system of IDSA to provide recommendations for other haematological diseases besides AML and recipients of an allogeneic haem atopoietic stem cell transplantation (HSCT).
Journal ArticleDOI
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
Raoul Herbrecht,Johan Maertens,L. Baila,Michel Aoun,Werner J. Heinz,Robert Martino,Stefan Schwartz,Andrew J. Ullmann,L Meert,Marianne Paesmans,Oscar Marchetti,Hamdi Akan,L. Ameye,Malathi Shivaprakash,C. Viscoli +14 more
TL;DR: Caspofungin first-line therapy was effective and well tolerated in allogeneic hematopoietic SCT patients with mycologically documented IA and no patient had a drug-related serious adverse event or discontinued because of toxicity.
Journal ArticleDOI
Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients
Leonardo Potenza,Daniela Vallerini,Patrizia Barozzi,Giovanni Riva,Fabio Forghieri,Eleonora Zanetti,Chiara Quadrelli,Anna Candoni,Johan Maertens,Giulio Rossi,Monica Morselli,Mauro Codeluppi,Ambra Paolini,Monica Maccaferri,Cinzia Del Giovane,Roberto D'Amico,Fabio Rumpianesi,Monica Pecorari,Francesca Cavalleri,Roberto Marasca,Franco Narni,Mario Luppi +21 more
TL;DR: Mucorales-specific T cells could be detected only in patients with IM, both at diagnosis and throughout the entire course of the IM, but neither before nor for long after resolution of the infection.
Journal ArticleDOI
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation.
Per Ljungman,Michael Schmitt,Francisco M. Marty,Johan Maertens,Roy F. Chemaly,Nicholas A. Kartsonis,Joan R. Butterton,Hong Wan,Valerie L Teal,Kendra Sarratt,Yoshihiko Murata,Randi Y. Leavitt,Cyrus Badshah +12 more
TL;DR: Letermovir may reduce mortality by preventing or delaying CS-CMVi in HCT recipients by blocking or delaying cytomegalovirus infections in patients with no detectable CMV DNA.